GlobalData on MSN18d
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
GlobalData on MSN12d
Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trial
The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children between two ...
Yahoo Finance19d
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
vaccine Abrysvo to include adults aged 18–59 years who have chronic conditions that place them at increased risk of lower respiratory tract disease caused by the virus. The label expansion adds ...